HJ-004 / Jing Medicine - LARVOL DELTA

HJ-004, a potent and selective pan-EGFR mutation targeted protein degrader (TPD) that effectively overcomes osimertinib resistance in EGFR-mutant NSCLC (AACR 2026) - "HJ-004 represents a first-in-class pan-EGFR mutation targeted protein degrader that effectively overcomes osimertinib resistance across classical, rare, and exon 20 insertion variants. Its potent degradation activity, broad antitumor efficacy, and favorable pharmacokinetic and safety profiles support advancement into clinical development as a next-generation therapy for EGFR-mutated NSCLC. HJ-004 was independently developed by Jing Medicine Technology (Shanghai) Ltd., and has received IND clearance from both the U.S. FDA and China NMPA."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Mutations (ChiCTR) - P1 | N=36 | Not yet recruiting | Sponsor: Shanghai East Hospital; Jing Medicine Technology (Shanghai) Co., Ltd.

New P1 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

HJ-004-02-101: A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Tongji University

New P1 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR